Fentanyl Buccal Lozenges (Actiq®)
... fentanyl buccal film dose has been determined, the patient should receive a prescription for the effective dosage strength and use or dispose of the remaining unused 200 mcg films. Fentanyl buccal films should not be torn or cut prior to use and will dissolve within 15 to 30 minutes following applic ...
... fentanyl buccal film dose has been determined, the patient should receive a prescription for the effective dosage strength and use or dispose of the remaining unused 200 mcg films. Fentanyl buccal films should not be torn or cut prior to use and will dissolve within 15 to 30 minutes following applic ...
tolerabiijty of multiple administration of intramuscular meloxicam
... experiencing at least one adverse event (Table III). No serious adverse events were reported in either group. The overall safety profile was similar to that previously observed with this class of drug and consisted mainly of GI events (gastric pain, nausea and diarrhoea), skin reactions (pruritus an ...
... experiencing at least one adverse event (Table III). No serious adverse events were reported in either group. The overall safety profile was similar to that previously observed with this class of drug and consisted mainly of GI events (gastric pain, nausea and diarrhoea), skin reactions (pruritus an ...
risperdal consta
... RISPERDAL CONSTA® every 2 weeks. No additional benefit was observed with dosages greater than 50 mg RISPERDAL CONSTA®; however, a higher incidence of adverse effects was observed. The efficacy of RISPERDAL CONSTA® in the treatment of schizophrenia has not been evaluated in controlled clinical tri ...
... RISPERDAL CONSTA® every 2 weeks. No additional benefit was observed with dosages greater than 50 mg RISPERDAL CONSTA®; however, a higher incidence of adverse effects was observed. The efficacy of RISPERDAL CONSTA® in the treatment of schizophrenia has not been evaluated in controlled clinical tri ...
Antiplatelet Drugs - OSU Center for Continuing Medical Education
... are receiving drugs that affect platelet function as a fundamental part of primary and secondary management of atherosclerotic thrombotic disease. There are several antiplatelet drugs available for use in clinical practice and several under investigation. Aspirin and clopidogrel (alone and in combin ...
... are receiving drugs that affect platelet function as a fundamental part of primary and secondary management of atherosclerotic thrombotic disease. There are several antiplatelet drugs available for use in clinical practice and several under investigation. Aspirin and clopidogrel (alone and in combin ...
butorphanol tartrate injection usp
... depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects. When used concurrently with such drugs, the dose of butorphanol should be the smallest effective dose and the frequency of dosing reduced as much as possibl ...
... depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects. When used concurrently with such drugs, the dose of butorphanol should be the smallest effective dose and the frequency of dosing reduced as much as possibl ...
Causes and Consequences of Increased Sympathetic Activity in
... characteristic of renal disease is unbalanced nitric oxide (NO) and angiotensin (Ang) activity. Increased SNA in renal disease may be sustained because a state of NO–Ang II unbalance is also present in the hypothalamus. Very few studies have directly compared the efficacy of adrenergic blockade with ...
... characteristic of renal disease is unbalanced nitric oxide (NO) and angiotensin (Ang) activity. Increased SNA in renal disease may be sustained because a state of NO–Ang II unbalance is also present in the hypothalamus. Very few studies have directly compared the efficacy of adrenergic blockade with ...
Chapter 15. Diuretic Agents
... The collecting tubule is responsible for only 2–5% of NaCl reabsorption by the kidney. Despite this small contribution, the collecting tubule plays an important role in renal physiology and in diuretic action. As the final site of NaCl reabsorption, the collecting tubule is responsible for volume re ...
... The collecting tubule is responsible for only 2–5% of NaCl reabsorption by the kidney. Despite this small contribution, the collecting tubule plays an important role in renal physiology and in diuretic action. As the final site of NaCl reabsorption, the collecting tubule is responsible for volume re ...
Full Text PDF
... 10.4 % of patients.22, 23 In a post marketing surveillance study performed in a cohort in the U.K. (n = 10,361 patients), dermatological medical events were reported by 341 ( 3 % ) of the patients.24 Most reactions were mild to moderate rashes occurring in the first 2 weeks and resolving within 2 - ...
... 10.4 % of patients.22, 23 In a post marketing surveillance study performed in a cohort in the U.K. (n = 10,361 patients), dermatological medical events were reported by 341 ( 3 % ) of the patients.24 Most reactions were mild to moderate rashes occurring in the first 2 weeks and resolving within 2 - ...
product information
... Atorvastatin and its metabolites are responsible for pharmacological activity in humans. The liver is its primary site of action and the principal site of cholesterol synthesis and LDL clearance. Drug dose rather than systemic drug concentration correlates better with LDL-C reduction. Individualisat ...
... Atorvastatin and its metabolites are responsible for pharmacological activity in humans. The liver is its primary site of action and the principal site of cholesterol synthesis and LDL clearance. Drug dose rather than systemic drug concentration correlates better with LDL-C reduction. Individualisat ...
Combined use of nonsteroidal anti-inflammatory drugs with diuretics
... and end-stage kidney disease and death.1 Nonsteroidal antiinflammatory drugs (NSAIDs) are estimated to account for up to 7% of all cases of AKI and up to 36% of drug-induced cases.2,3 NSAID exposure has been reported to increase the risk of AKI between 1.3- and 4.1-fold and the number needed to harm ...
... and end-stage kidney disease and death.1 Nonsteroidal antiinflammatory drugs (NSAIDs) are estimated to account for up to 7% of all cases of AKI and up to 36% of drug-induced cases.2,3 NSAID exposure has been reported to increase the risk of AKI between 1.3- and 4.1-fold and the number needed to harm ...
NORTRIPTYLINE 10MG TABLETS NORTRIPTYLINE 25MG TABLETS UKPAR
... Nortriptyline hydrochloride is the subject of a European Pharmacopoeia monograph. Synthesis of the drug substance from the designated starting materials has been adequately described and appropriate in-process controls and intermediate specifications are applied. Satisfactory specification tests are ...
... Nortriptyline hydrochloride is the subject of a European Pharmacopoeia monograph. Synthesis of the drug substance from the designated starting materials has been adequately described and appropriate in-process controls and intermediate specifications are applied. Satisfactory specification tests are ...
DOCEtaxel - Cancer Care Ontario
... may be severe with ascites, pleural or pericardial effusions. Peripheral edema can be treated with standard measures (e.g. sodium restriction, diuretics). Premedication with oral corticosteroids has been reported to delay the onset and decrease the severity of fluid retention, and all patients sho ...
... may be severe with ascites, pleural or pericardial effusions. Peripheral edema can be treated with standard measures (e.g. sodium restriction, diuretics). Premedication with oral corticosteroids has been reported to delay the onset and decrease the severity of fluid retention, and all patients sho ...
Epclusa - Gilead
... Adverse Reactions in Subjects with Decompensated Cirrhosis The safety assessment of EPCLUSA in subjects infected with genotype 1, 2, 3, 4, or 6 HCV with decompensated cirrhosis was based on one Phase 3 trial (ASTRAL-4) including 87 subjects who received EPCLUSA with ribavirin for 12 weeks. All 87 su ...
... Adverse Reactions in Subjects with Decompensated Cirrhosis The safety assessment of EPCLUSA in subjects infected with genotype 1, 2, 3, 4, or 6 HCV with decompensated cirrhosis was based on one Phase 3 trial (ASTRAL-4) including 87 subjects who received EPCLUSA with ribavirin for 12 weeks. All 87 su ...
full prescribing information
... Patients who are using drugs that suppress the immune system are more susceptible to infections than healthy individuals. Chicken pox and measles, for example, can have a more serious or even fatal course in susceptible children or adults using corticosteroids. In children or adults who have not had ...
... Patients who are using drugs that suppress the immune system are more susceptible to infections than healthy individuals. Chicken pox and measles, for example, can have a more serious or even fatal course in susceptible children or adults using corticosteroids. In children or adults who have not had ...
FLUNIXIN - American Academy of Veterinary Pharmacology and
... Other studies using models of endotoxemia in horses have shown that 0.25 mg of flunixin per kg of body weight every eight hours will provide dose-dependent suppression of eicosanoid synthesis, while not relieving all clinical signs; the level of pain relief provided by this dose was not assessed.EL{ ...
... Other studies using models of endotoxemia in horses have shown that 0.25 mg of flunixin per kg of body weight every eight hours will provide dose-dependent suppression of eicosanoid synthesis, while not relieving all clinical signs; the level of pain relief provided by this dose was not assessed.EL{ ...
Slide Set
... Do not use EMEND concurrently with pimozide, terfenadine, astemizole, cisapride Caution is advised when EMEND is administered with the following chemotherapeutic agents: etoposide, vinorelbine, docetaxel, and paclitaxel ...
... Do not use EMEND concurrently with pimozide, terfenadine, astemizole, cisapride Caution is advised when EMEND is administered with the following chemotherapeutic agents: etoposide, vinorelbine, docetaxel, and paclitaxel ...
Is there any role of fluoxetine in adenomyosis: An animal experiment
... Maintenance of the animals as well all the procedures of the experiment was as per the CPCSEA guideline. The animals were adapted to their new surroundings for three days before the initiation of the experiment. The 18 rats were divided into three groups, namely, I (vehicle treated control group), I ...
... Maintenance of the animals as well all the procedures of the experiment was as per the CPCSEA guideline. The animals were adapted to their new surroundings for three days before the initiation of the experiment. The 18 rats were divided into three groups, namely, I (vehicle treated control group), I ...
PRODUCT MONOGRAPH FLECAINIDE Flecainide
... tachyarrhythmias, the remainder being increased frequency of PVCs or new supraventricular arrhythmias. In patients with complex ventricular arrhythmias, it is often difficult to distinguish a spontaneous variation in the patient's underlying rhythm disorder from drug-induced worsening, so that the f ...
... tachyarrhythmias, the remainder being increased frequency of PVCs or new supraventricular arrhythmias. In patients with complex ventricular arrhythmias, it is often difficult to distinguish a spontaneous variation in the patient's underlying rhythm disorder from drug-induced worsening, so that the f ...
Safety and Efficacy of Oxcarbazepine - Deep Blue
... two-arm, parallel-group inpatient trial in patients aged 11–65 years undergoing evaluation for epilepsy surgery. 14 After completion of their presurgical diagnostic evaluation, patients who had their AEDs discontinued and who satisfied the inclusion and exclusion criteria were randomized to treatmen ...
... two-arm, parallel-group inpatient trial in patients aged 11–65 years undergoing evaluation for epilepsy surgery. 14 After completion of their presurgical diagnostic evaluation, patients who had their AEDs discontinued and who satisfied the inclusion and exclusion criteria were randomized to treatmen ...
ภาพนิ่ง 1
... Adapted from Kastelein JJP, et al. Am Heart J. 2005;149:234–239; Baigent C, Landry M. Kidney Int. 2003;63(suppl 84):S207–S210; Oxford Clinical Trial Service Unit. The Study of Heart and Renal Protection (SHARP). Available at: http://www.ctsu.ox.ac.uk/ ~sharp/. Accessed June 2005; Rossebo A, et al, f ...
... Adapted from Kastelein JJP, et al. Am Heart J. 2005;149:234–239; Baigent C, Landry M. Kidney Int. 2003;63(suppl 84):S207–S210; Oxford Clinical Trial Service Unit. The Study of Heart and Renal Protection (SHARP). Available at: http://www.ctsu.ox.ac.uk/ ~sharp/. Accessed June 2005; Rossebo A, et al, f ...
AROPAX® PRODUCT INFORMATION (paroxetine)
... Elimination Approximately 64% of the dose is excreted in the urine; urinary excretion of unchanged paroxetine is generally less than 2% of dose. About 36% of the dose is excreted in the faeces, probably via the bile; faecal excretion of unchanged paroxetine represents less than 1% of the dose. Thus ...
... Elimination Approximately 64% of the dose is excreted in the urine; urinary excretion of unchanged paroxetine is generally less than 2% of dose. About 36% of the dose is excreted in the faeces, probably via the bile; faecal excretion of unchanged paroxetine represents less than 1% of the dose. Thus ...
ramelteon
... and safety of the product, the occurrence of impaired consciousness (memory impairment during interim periods of wakefulness, etc.), the occurrence of withdrawal symptoms, rebound insomnia, abuse and dependence, and muscle relaxation such as staggering, which are problematic events associated with c ...
... and safety of the product, the occurrence of impaired consciousness (memory impairment during interim periods of wakefulness, etc.), the occurrence of withdrawal symptoms, rebound insomnia, abuse and dependence, and muscle relaxation such as staggering, which are problematic events associated with c ...
Epzicom Tablets
... following a hypersensitivity reaction to abacavir, regardless of HLA-B*5701 status. • To reduce the risk of a life-threatening hypersensitivity reaction, regardless of HLA-B*5701 status, discontinue EPZICOM immediately if a hypersensitivity reaction is suspected, even when other diagnoses are possib ...
... following a hypersensitivity reaction to abacavir, regardless of HLA-B*5701 status. • To reduce the risk of a life-threatening hypersensitivity reaction, regardless of HLA-B*5701 status, discontinue EPZICOM immediately if a hypersensitivity reaction is suspected, even when other diagnoses are possib ...
Emtricitabine / rilpivirine / tenofovir disoproxil fumarate
... amino acid substitutions that emerged included: L100I, K101E, V108I, E138K, V179F, Y181C, H221Y, F227C and M230I. In Clinical Studies: Treatment-Naïve Patients Considering all of the available in vitro and in vivo data in treatment-naïve patients the following resistance-associated substitutions, wh ...
... amino acid substitutions that emerged included: L100I, K101E, V108I, E138K, V179F, Y181C, H221Y, F227C and M230I. In Clinical Studies: Treatment-Naïve Patients Considering all of the available in vitro and in vivo data in treatment-naïve patients the following resistance-associated substitutions, wh ...
A Practical Guide for Clinicians Who Treat Patients with Amiodarone
... have been reported. The typical long-term side effects seen with oral amiodarone are seen rarely with acute IV dosing. Use in Pregnant Patients Amiodarone is not well-studied in pregnant patients. Amiodarone crosses the placental barrier, although fetal serum levels are only 10 –25% of maternal leve ...
... have been reported. The typical long-term side effects seen with oral amiodarone are seen rarely with acute IV dosing. Use in Pregnant Patients Amiodarone is not well-studied in pregnant patients. Amiodarone crosses the placental barrier, although fetal serum levels are only 10 –25% of maternal leve ...
Ofloxacin
Ofloxacin is a synthetic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone.Ofloxacin was first patented in 1982 (European Patent Daiichi) and received approval from the U.S. Food and Drug Administration (FDA) on December 28, 1990. Ofloxacin is sold under a wide variety of brand names as well as generic drug equivalents, for oral and intravenous administration. Ofloxacin is also available for topical use, as eye drops and ear drops (marketed as Ocuflox and Floxin Otic respectively in the United States and marketed as Optiflox, eylox respectively in Jordan and Saudi Arabia).Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its “mirror image” or enantiomer dextrofloxacin.Ofloxacin has been associated with adverse drug reactions, such as tendon damage (including spontaneous tendon ruptures) and peripheral neuropathy (which may be irreversible); tendon damage may manifest long after therapy had been completed, and, in severe cases, may result in lifelong disabilities.